Blog
RSS FeedPosted by Michael Wonder on 09 Mar 2025
Expanded reimbursement for Rinvoq enhances atopic dermatitis treatment options
7 March 2025 - Korean patients with moderate to severe atopic dermatitis now have greater flexibility in treatment as reimbursement ...
Posted by Michael Wonder on 05 Mar 2025
Obesity management needs medications on PBS: RACGP
4 March 2025 - The college’s new obesity position statement calls for extra funding to treat the complex condition and for ...
Posted by Michael Wonder on 04 Mar 2025
Roche Korea’s multiple sclerosis drug scores reimbursement
4 March 2025 - Roche Korea said its multiple sclerosis treatment, Ocrevus (ocrelizumab), started receiving reimbursement from last Saturday. ...
Posted by Michael Wonder on 03 Mar 2025
Amyloid cardiomyopathy drug Vyndamax to get health insurance from March
28 February 2025 - Vyndamax (tafamidis), a transthyretin amyloid cardiomyopathy medicine that has experienced difficulties getting on the health insurance ...
Posted by Michael Wonder on 03 Mar 2025
Cushing’s disease: drug added to PBS
2 March 2025 - Australians suffering from the debilitating condition Cushing’s disease have scored a huge win after a vital ...
Posted by Michael Wonder on 01 Mar 2025
Bimzelx (bimekizumab) negotiations with pCPA concluded successfully following positive CDA and INESSS recommendations for adults with active psoriatic arthritis and adults with active ankylosing spondylitis
28 February 2025 - Positive CDA and INESSS reimbursement recommendations are an important step towards public access to Bimzelx, the first ...
Posted by Michael Wonder on 27 Feb 2025
Health insurers worried about court order to cover expensive cancer medicines
26 February 2025 - Health insurance companies are “very concerned” about their ability to force lower prices being restricted after a ...
Posted by Michael Wonder on 23 Feb 2025
HIRA to remove 17 medicines from group 2 anti-cancer list, update reimbursement criteria
21 February 2025 - Korea's HIRA said it has decided to remove 17 medicines from the list of group 2 ...
Posted by Michael Wonder on 14 Feb 2025
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance successfully finalise negotiations for Apretude for HIV-1 pre-exposure prophylaxis
13 February 2025 - ViiV Healthcare is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance ...
Posted by Michael Wonder on 09 Feb 2025
Albanese Labor Government strengthening Medicare with over $500 million for women's health
9 February 2025 - The Albanese Labor Government is building Australia’s future and strengthening Medicare, today announcing $573.3 million to deliver ...
Posted by Michael Wonder on 05 Feb 2025
Medexus and Ontario's Provincial Health Services successfully complete agreements for public reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
4 February 2025 - Medexus recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario ...
Posted by Michael Wonder on 04 Feb 2025
Insurer denies access to drugs granted accelerated approval by FDA
3 January 2025 - An insurer’s decision to delay reimbursement of drugs licensed under the FDA’s accelerated approval program has sparked ...
Posted by Michael Wonder on 02 Feb 2025
Life-saving lung cancer drug added to PBS, slashing price from $10,000 a month to $30 per script
1 February 2025 - Australians diagnosed with a rare form of lung cancer will now have access to a life-saving ...
Posted by Michael Wonder on 02 Feb 2025
Cheaper medicine for lung cancer patients
2 February 2025 - The Australian Government is listing Retevmo (selpercatinib) on the PBS for the first time to treat advanced ...
Posted by Michael Wonder on 01 Feb 2025
Groundbreaking one-off gene therapy approved for severe sickle cell disease
31 January 2025 - People in England with severe sickle cell disease will be among the first to receive treatment using ...